Faisal Zain has spent the last decade at the intersection of medical manufacturing and diagnostic innovation, carving out a reputation as a visionary in how we treat complex metabolic disorders. As a healthcare expert who has overseen the development of cutting-edge medical devices and therapeutic delivery systems, he possesses a unique perspective on the physiological “glitches” that can occur following major surgical interventions. Today, his focus is on the evolving landscape of post-bariatric hypoglycemia, a condition that has long been a shadow over the success of weight-loss surgeries. Our conversation explores the metabolic shifts that occur when the human gut is surgically altered, the biological mechanism of a new class of GLP-1 antagonists, and the potential for these therapies to restore independence to thousands of patients.
The discussion delves into the clinical mechanics of how surgical changes to the digestive tract trigger an overproduction of insulin, leading to dangerous drops in blood sugar. We examine the Phase 3 trial data for avexitide, which has shown a remarkable 55% reduction in hypoglycemic events, and discuss the strategic pivot of pharmaceutical companies toward rare disease markets. Finally, we look at the patient experience, where the constant threat of seizures and cognitive impairment creates a life of isolation, and how new daily and weekly treatments are poised to rewrite the narrative for those suffering from this chronic condition.
How does post-bariatric hypoglycemia fundamentally strip away a patient’s independence and change their daily cognitive reality?
When we talk about post-bariatric hypoglycemia, or PBH, we aren’t just talking about a mild dizzy spell after a meal; we are talking about a total metabolic betrayal. Imagine a patient who has undergone a successful weight-loss surgery, only to find that every time they eat, their blood sugar plunges so low that they experience debilitating “brain fog,” severe dizziness, or even full-blown seizures. This cognitive dysfunction isn’t just a temporary annoyance—it is a barrier that prevents 160,000 people in the U.S. from performing basic tasks like driving a car or looking after their children. For these individuals, the fear of losing consciousness in a grocery store or at their desk creates a self-imposed prison of isolation. It turns a life-saving surgery into a chronic, life-altering condition that requires constant, hyper-vigilant monitoring of every single bite of food.
Can you explain the biological “glitch” that occurs after gastric bypass surgery which leads to such abnormally high GLP-1 levels?
The human body is an incredible machine, but when we perform a Roux-en-Y gastric bypass, we are essentially rewiring the plumbing of the gut in a way that the anatomy didn’t originally intend. This surgical alteration changes how food interacts with the intestinal lining, which can cause the gastrointestinal hormone GLP-1 to skyrocket to levels that are far beyond the healthy range. In a normal system, GLP-1 helps regulate insulin, but when it is excessively high, it sends the pancreatic islet beta cells into overdrive. They release a massive surge of insulin, which then aggressively clears glucose from the blood, leading to that terrifying “steep drop” in sugar levels. It’s a paradox where the very hormones we usually try to boost for weight loss become the primary antagonists to a patient’s stability and safety.
How does the mechanism of avexitide differ from the popular GLP-1 weight-loss drugs that have dominated the headlines recently?
The distinction is critical because they are essentially two sides of the same coin, but working in opposite directions. The obesity drugs everyone is familiar with are agonists, meaning they bind to and activate the GLP-1 receptor to slow digestion and signal fullness. Avexitide, on the other hand, is an antagonist—a peptide specifically engineered to bind to those same receptors on the pancreatic beta cells but for the purpose of blocking them. By acting as a “shield,” avexitide prevents the excessively high levels of GLP-1 from triggering that massive insulin spike. It’s about bringing a chaotic, overactive system back into a healthy, balanced range rather than trying to stimulate it further.
Looking at the Phase 3 study involving 78 participants, what do the results tell us about the efficacy and safety profile of this daily treatment?
The data from this pivotal study is incredibly encouraging, particularly the 55% reduction in hypoglycemic events through the 16-week mark. When you consider that these 78 participants were struggling with severe symptoms after Roux-en-Y surgery, seeing more than half of those dangerous episodes disappear is a massive clinical win. From a safety perspective, the drug was generally well tolerated, with most side effects being mild to moderate, such as injection site reactions or diarrhea. Perhaps the most telling statistic is that in one major clinical site, not a single participant discontinued the therapy, and every one of them chose to move into the open-label extension study. That speaks volumes about the perceived benefit versus the minor discomfort of a daily injection.
What does it mean for a patient to “return to work” after being disabled by this condition, and how does that impact the broader family dynamic?
The impact is truly “life-altering,” a phrase we don’t use lightly in the medical community. When a patient can return to work, it isn’t just about a paycheck; it’s about the restoration of their identity and the removal of a massive burden from their family members. We’ve heard stories of patients who could finally function independently again, no longer needing a spouse or a caregiver to watch them every time they finished breakfast. The psychological relief of knowing you won’t collapse in front of your children is immeasurable. By providing a stable metabolic floor, we are giving these people the ability to engage with the world on their own terms again, which is the ultimate goal of any innovative therapy.
How did the strategic acquisition of this drug candidate help reshape the company’s trajectory after their previous challenges in the ALS market?
It was a bold and necessary pivot that demonstrates the importance of resilience in biotech manufacturing. After the disappointment with their ALS drug, Relyvrio, the leadership looked at hundreds of candidates before finding this peptide in a bankruptcy auction. They weren’t looking for a “me too” drug that offered a marginal improvement over existing options; they wanted to solve a disease that had virtually no treatment options. By securing avexitide, they moved from a place of uncertainty to leading a program for a condition that affects roughly 120,000 gastric bypass patients. It’s a classic example of finding a high-need, rare-disease niche where a single innovative molecule can define a company’s entire future.
Why is daily dosing not considered a significant hurdle for patient adoption in the case of post-bariatric hypoglycemia?
In many chronic conditions, adherence is a struggle because the disease is asymptomatic—you don’t “feel” high cholesterol, so you might forget your pill. PBH is the exact opposite; the consequences of missing a dose are immediate, visceral, and terrifying. If a patient misses their morning injection, which must be taken at least 60 minutes before breakfast, they face a high probability of a hypoglycemic crash within hours. This creates an extreme level of internal motivation to stick to the regimen. As clinicians have observed, when the alternative is a seizure or loss of consciousness, a daily injection becomes a small price to pay for the security of knowing you will remain upright and lucid throughout the day.
Can you elaborate on the next-generation pipeline, specifically AMX0318, and what it promises for the future of PBH treatment?
While the daily injection is a life-saver, we are always looking for ways to reduce the “treatment burden” on the patient. AMX0318 is a next-generation GLP-1 antagonist that we are developing in partnership with Gubra, and it holds the potential for weekly dosing rather than daily. We are currently in the late stages of preclinical development and are on track to begin clinical testing in 2027. Moving from 365 injections a year to just 52 would be a monumental shift in quality of life. It’s about taking the proven efficacy of the antagonist approach and refining the delivery system to be as non-intrusive as possible, ensuring long-term success for the patient.
With other companies testing oral small molecules like mizagliflozin, how do you see the competitive landscape shifting by the time we reach 2027?
The competition is a sign that the medical community has finally recognized the scale of this unmet need. You have Recordati working on pasireotide, which should have a finalized Phase 3 plan by the end of this year, and Vogenx exploring an oral SLGT1 inhibitor with data expected in 2027. However, the results we’ve seen with avexitide suggest a profile that is very hard to beat, particularly because it targets the GLP-1 receptor directly—the “heart” of the PBH issue. Having multiple approaches is good for patients, but being the first to market with a 55% reduction rate sets a very high bar for any oral or alternative peptide therapy that follows.
What is your forecast for the treatment of metabolic complications over the next few years?
I believe we are entering an era where bariatric surgery will no longer be seen as a “one and done” procedure, but as the start of a managed metabolic journey. Even as obesity drugs become more prevalent, surgery remains the gold standard for severe cases, and as that patient population grows, so will the need for sophisticated post-operative care. I expect that by 2027, with the launch of avexitide, we will see peak sales reaching between $1 billion and $1.5 billion, reflecting just how many people have been suffering in silence. We are moving toward a future where “precision metabolism” allows us to fix the unintended side effects of surgery with the same level of accuracy that we used to perform the surgery itself.
